Key Takeaways:
- Alphamin forecasts record Q1 2026 EBITDA of US$158 million.
- The announcement points to strong profitability for the tin miner.
- Guidance comes alongside a new exploration update for its projects.
Key Takeaways:

Alphamin Resources Corp. (AFM:TSXV, APH:JSE AltX) announced record first-quarter EBITDA guidance of US$158 million for the period ending March 31, 2026, signaling strong operational performance and profitability.
The forecast, detailed in a corporate update, represents a new benchmark for the company's quarterly earnings. While the firm did not provide specific revenue or earnings-per-share metrics, the record EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) figure points to robust margins and efficient production.
"The announcement of record EBITDA guidance is highly likely to drive positive investor sentiment," the company stated in its release. The update also included information regarding its ongoing exploration programs, which are key to future growth.
The record guidance is expected to fuel positive investor sentiment for the TSXV- and JSE-listed tin producer. The figure suggests a significant jump in profitability that could provide a substantial lift to Alphamin's share price as investors digest the strong forward-looking statement.
Alongside the financial guidance, Alphamin provided an update on its exploration activities. Continued success in defining new resources is critical for the company to maintain its production profile and capitalize on strong tin prices. The company's primary asset is the high-grade Mpama North mine in the Democratic Republic of Congo, and it is developing the adjacent Mpama South project.
The strong guidance sets a bullish tone for the upcoming full financial results. Investors will be watching for the detailed earnings report to confirm revenue growth and cost controls, alongside further results from the company's ongoing exploration activities.
This article is for informational purposes only and does not constitute investment advice.